Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - hydrochlorothiazide, quantity: 12.5 mg; eprosartan mesilate, quantity: 735.8 mg (equivalent: eprosartan, qty 600 mg) - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; iron oxide yellow; purified talc; polyvinyl alcohol; iron oxide black; macrogol 3350 - teveten plus is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - eprosartan mesilate, quantity: 735.8 mg (equivalent: eprosartan, qty 600 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; pregelatinised maize starch; hypromellose; macrogol 400; polysorbate 80; titanium dioxide - teveten is indicated for the treatment of essential hypertension.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - eprosartan mesilate, quantity: 400 mg (equivalent: eprosartan mesilate, qty 400 mg) - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; titanium dioxide; hypromellose; polysorbate 80; iron oxide yellow; iron oxide red; macrogol 400 - teveten is indicated for the treatment of essential hypertension.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - eprosartan mesylate (unii: 8n2l1nx8s3) (eprosartan - unii:2kh13z0s0y), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - eprosartan 600 mg - teveten® hct is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensives such as calcium channel blockers. this fixed dose combination is not indicated for initial therapy (see dosage and administration ). teveten® hct is contraindicated in patients who are hypersensitive to this product or any of its components. because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - eprosartan; eprosartan mesylate -

Australia - English - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - eprosartan; hydrochlorothiazide -

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - eprosartan - film-coated tablet - 600 milligram(s) - angiotensin ii antagonists, plain; eprosartan

Malta - English - Medicines Authority

abbott healthcare products limited - eprosartan 600 mg - film-coated tablet

Ireland - English - HPRA (Health Products Regulatory Authority)

bgp products ltd - eprosartan mesylate - film coated tablet - 400 milligram - angiotensin ii antagonists, plain - angiotensin-ii antagonists, plain c - eprosartan is indicated for the treatment of essential hypertension.

Ireland - English - HPRA (Health Products Regulatory Authority)

bgp products ltd - eprosartan mesylate - film coated tablet - 600 milligram - angiotensin ii antagonists, plain - angiotensin-ii antagonists, plain c - eprosartan is indicated for the treatment of essential hypertension